



PI : Prof. I-Jong Wang

Department of Ophthalmology, College of Medicine, National Taiwan University

Experience:

1994/08 till now, Attending staff in corneal section, Department of Ophthalmology, NTUH

2013/08 till now, Professor, Department of Ophthalmology, College of Medicine, National Taiwan University

2011/08-2013/07, Associated Professor, Department of Ophthalmology, College of Medicine, National Taiwan University

2007/02-2011/07, Clinical Associate professor, Department of Ophthalmology, NTUH.

2002/02-2007/01, Clinical Assistant professor, Department of Ophthalmology, NTUH.

Market Needs:

Myopia is a very serious health problem in Asian countries, especially in Hans population. Complications of myopia include retinal degeneration, maculopathy, cataract and glaucoma which are the main causes of blindness in myopic patients. In Taiwan and also in Asian, approximately 85% of the senior high school students in these countries have myopia. Myopia can only be controlled once the myopia is formed, and current treatment modalities only cycloplegics (Atropine eye drop). But Atropine eye drop may make eyes more sensitive to sunlight.

Our Technology:

We have successfully established an animal model for the study of eye diseases. And fortunately, we apply our model to screen possible candidate drugs which can effectively control eyeball size elongation which is compatible with the pathology of myopia progression.

Strength:

Replace atropine eye drops which is the only myopia progression controlling drug, and without side effects such as temporary blurred vision and dilated pupils, sensitive to sunlight, and long-term use may result in macular damage due to excess exposure to light.

Competing Products:

There is no competing products in the world

Intellectual Properties:

- (1) Patent Pending (including USA, Japan 、European 、Indonesia 、India 、Malaysia 、Singapore 、Korea) 、Patent in Taiwan has been approved
- (2) Some candidate drugs in our results have FDA approved and used in clinical for long time. Preclinical toxicity and pharmacokinetics tests can be reduced, and access to human clinical trials quickly.

Contact (do not need to fill out):

Center for Industry-Academia Cooperation, NTU

Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw

